Acrivon Therapeutics, Inc. 8-K

What Happened
Acrivon Therapeutics (ACRV) filed an 8-K on January 8, 2026 disclosing preliminary, unaudited cash, cash equivalents and investments of approximately $119 million as of December 31, 2025 and announcing a press release with interim clinical data for its AP3-driven programs. The company said this cash position, based on current operating plans, is expected to fund operations into the second quarter of 2027. The press release (Exhibit 99.1) highlights updated ACR-368 Phase 2b registrational-intent results, initial ACR-2316 Phase 1 data, and nomination of ACR-6840 (CDK11 inhibitor) with an IND target in Q4 2026.

Key Details

• Preliminary cash: ~$119 million as of Dec 31, 2025; runway expected into Q2 2027 based on current plans (Item 2.02).
• ACR-368 (CHK1/CHK2 inhibitor) Phase 2b interim results: Arm 1 (BM+ monotherapy) ORR 39%; in subjects with ≤2 prior lines ORR 44%. In serous endometrial cancer (EC) the combined ORR (cORR) was 67% in BM+ (N=12) and 52% in serous subjects overall (N=23) vs 22% in non-serous (N=37). Based on higher serous responses, Arm 3 will enroll only serous EC (≤2 prior LoT); EU CTA filed and initial EU enrollment expected Q1 2026.
• ACR-2316 (WEE1/PKMYT1 inhibitor) Phase 1: 33 patients dosed (EDC as of Dec 22, 2025); two weekly oral regimens established (160 mg QD 3d on/4d off and 240 mg QD 2d on/5d off) with manageable, mostly neutropenia-related AEs. Tumor shrinkage seen at ≥120 mg in 9/20 evaluable patients, including a confirmed PR in endometrial cancer.
• ACR-6840 nominated as next development candidate (CDK11); IND submission anticipated Q4 2026.

Why It Matters
For investors, the filing provides two practical takeaways: Acrivon has about $119M in liquidity that the company says should fund operations into Q2 2027, giving time to advance multiple clinical milestones; and the reported interim clinical signals—especially stronger responses in serous EC for ACR-368 and early tumor responses with ACR-2316—support continued development and planned expansions (EU Arm 3 enrollment, Phase 3 readiness, and an IND for ACR-6840). These data are interim and preliminary (some based on EDC extracts) and the company notes forward-looking statements and customary risks.